What do CRISPR and longevity have in common? Not much, except it's all molecular.

We spoke to two different CEOs focused on improving human health. We begin with Dr Benjamin Oakes, Co-Founder, President, and CEO of Scribe Therapeutics, who takes us through the discovery, potential, and possible limitations of CRISPR.

Then we are joined by fellow visionary Kristen Fortney, the CEO and co-founder of BioAge, a clinical-stage biotechnology company developing therapies that treat disease by targeting the biology of ageing.

You cannot miss these fascinating conversations.

Transcript

Keywords: ageing, CRISPR, molecules, age, technology, disease, muscle, engineering, treat, understand, genome editing, human, Jennifer Doudna.